Der var imidlertid ingen sammenhæng mellem forekomst af bivirkninger relateret til galdevejen hos darifenacinbehandlede patienter og stigende alder.
However, there was no association between the occurrence of adverse events related to the biliary system in darifenacin-treated patients and increasing age.